Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued on Friday, American Banking News reports. They currently have a $167.00 price objective on the stock. Zacks‘ target price indicates a potential upside of 4.99% from the company’s current price. Zacks‘ analyst wrote, “We are initiating coverage on […]
Jazz Pharmaceuticals Plc’s “Neutral” Rating Reaffirmed at Zacks (JAZZ) is a post from: Zolmax
The post Jazz Pharmaceuticals Plc’s “Neutral” Rating Reaffirmed at Zacks (JAZZ) appeared first on Zolmax.